[go: up one dir, main page]

TW200800959A - Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor - Google Patents

Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor

Info

Publication number
TW200800959A
TW200800959A TW095120358A TW95120358A TW200800959A TW 200800959 A TW200800959 A TW 200800959A TW 095120358 A TW095120358 A TW 095120358A TW 95120358 A TW95120358 A TW 95120358A TW 200800959 A TW200800959 A TW 200800959A
Authority
TW
Taiwan
Prior art keywords
agonists
piperazine
ht1a receptor
compounds
piperidine
Prior art date
Application number
TW095120358A
Other languages
English (en)
Inventor
Wayne Everett Childers
Magda Asselin
George Theodore Grosu
Annmarie Louise Sabb
Lisa Marie Havran
Zhongqi Shen
James Jacob Bicksler
Dan Chae-Koo Chong
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of TW200800959A publication Critical patent/TW200800959A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW095120358A 2005-06-10 2006-06-08 Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor TW200800959A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68946905P 2005-06-10 2005-06-10

Publications (1)

Publication Number Publication Date
TW200800959A true TW200800959A (en) 2008-01-01

Family

ID=37530084

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095120358A TW200800959A (en) 2005-06-10 2006-06-08 Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor

Country Status (20)

Country Link
US (1) US7671056B2 (zh)
EP (1) EP1888559A2 (zh)
JP (1) JP2008543782A (zh)
KR (1) KR20080021134A (zh)
CN (1) CN101243073A (zh)
AR (1) AR055059A1 (zh)
AU (1) AU2006257874A1 (zh)
BR (1) BRPI0613491A2 (zh)
CA (1) CA2611711A1 (zh)
CR (1) CR9560A (zh)
EC (1) ECSP088094A (zh)
GT (1) GT200600255A (zh)
IL (1) IL187972A0 (zh)
MX (1) MX2007015678A (zh)
NO (1) NO20076344L (zh)
PE (1) PE20070069A1 (zh)
RU (1) RU2007146543A (zh)
TW (1) TW200800959A (zh)
WO (1) WO2006135839A2 (zh)
ZA (1) ZA200710699B (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
CN101466365A (zh) * 2006-06-09 2009-06-24 惠氏公司 增强认知功能的方法
TW200808730A (en) * 2006-06-09 2008-02-16 Wyeth Corp Process for synthesizing piperazine-piperidine compounds
AR063984A1 (es) * 2006-11-28 2009-03-04 Wyeth Corp Metabolitos de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina, metodos de preparacion, su uso en la fabricacion de medicamentos para el tratamiento de trastornos relacionados con 5-ht1a, composicion farmaceutica que los comprende, compuestos radioetiquetados derivado
CL2007003409A1 (es) * 2006-11-28 2008-04-11 Wyeth Corp Perla de liberacion controlada que comprende una unidad de nucleo central, una primera capa con un agente farmacologico que es un compuesto derivado de piperazina-piperidina, un acidificante, una segunda capa; procedimiento de preparacion; formulacio
AR065376A1 (es) * 2007-02-16 2009-06-03 Wyeth Corp Formulacion de pastillas de liberacion sostenida de antagonistas y agonistas de piperazina - piperidina del receptor 5 ht1a que tienen disolucion instestinal mejorada
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
WO2010081851A1 (en) 2009-01-14 2010-07-22 Genoscience Pharma Piperidin-4-ylpiperazine compounds for the treatment of hcv infection
CN101797223B (zh) * 2009-02-06 2012-05-23 上海交通大学医学院 石杉碱甲眼用制剂及其应用
EP3061821B1 (en) * 2009-07-22 2019-07-10 Puretech Health LLC Compositions for treatment of disorders ameliorated by muscarinic receptor activation
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP3856182B1 (en) 2018-09-28 2025-12-24 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
KR20250129556A (ko) 2024-02-22 2025-08-29 단국대학교 천안캠퍼스 산학협력단 Fk960을 유효성분으로 포함하는 신경 질환 예방 또는 치료용 약학 조성물

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2908952C3 (de) 1979-03-07 1981-12-03 Gerhard Hug Gmbh, 7801 Umkirch Drainagevorrichtung
US4665183A (en) 1985-12-20 1987-05-12 American Home Products Corp. Process for preparing 6,7,8,9-tetrahydro-10-methylpyrido[1,2-a]indol-9-amines and derivatives thereof useful for the treatment of cognitive impairments
US4624954A (en) 1985-12-20 1986-11-25 American Home Products Corporation 6,7,8,9-tetrahydro-10-methylpyrido[1,2-a]indol-9-amines and derivatives thereof, useful for the treatment of cognitive impairments
US5219857A (en) 1986-10-16 1993-06-15 American Cyanamid Company Method of treating cognitive and related neural behavioral problems
US4904658A (en) 1988-04-15 1990-02-27 American Cyanamid Company Substituted-6H,8H-pyrimido-[1,2,3-cd]purine-8,10-(9H)-diones and substituted-6H,10H-pyrimido[1,2-cd]purin-10-ones
US5260331A (en) 1989-01-02 1993-11-09 John Wyeth & Brother Limited Composition for treating depression with (S- or O-heteroaryl)alkyl amines
US5422355A (en) 1989-06-02 1995-06-06 John Wyeth & Brother, Limited Composition for treating depression with (N-heteroaryl)alkylamines
ES2130135T3 (es) 1990-01-11 1999-07-01 Upjohn Co Nuevos compuestos heterociclicos de 6,7,8,9-tetrahidro-3h-benz(e)indol con actividad terapeutica sobre el sistema nervioso central.
MX9201991A (es) 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
GB9125615D0 (en) 1991-12-02 1992-01-29 Wyeth John & Brother Ltd Amines
PT651746E (pt) 1992-07-24 2002-09-30 Univ California Drogas que intensificam as respostas sinapticas mediadas por receptores de ampa
DK0674641T3 (da) 1992-12-17 1999-09-27 Pfizer Pyrrolopyrimidiner som CRF-antagonister
AU690079B2 (en) 1992-12-17 1998-04-23 Pfizer Inc. Substituted pyrazoles as CRF antagonists
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
DE69323212T2 (de) 1992-12-17 1999-05-27 Pfizer Inc., New York, N.Y. Pyrazole mit crf antagonistischer aktivität
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
GB9411099D0 (en) 1994-06-03 1994-07-27 Wyeth John & Brother Ltd Piperazine derivatives
US5650409A (en) 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
GB9514901D0 (en) 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives
US5736543A (en) 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
CA2255612A1 (en) 1996-05-31 1997-12-04 Pharmacia & Upjohn Company Aryl substituted cyclic amines as selective dopamine d3 ligands
US5891885A (en) 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6329368B1 (en) 1997-05-09 2001-12-11 The Regents Of The University Of California Endocrine modulation with positive modulators of AMPA type glutamate receptors
HUP0101280A3 (en) 1998-02-18 2003-02-28 Neurosearch As Positive ampa receptor modulator compounds and their use
US6124278A (en) 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
SE9804126D0 (sv) 1998-11-27 1998-11-27 Astra Ab New pharmaceutical composition
US6313126B1 (en) 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
DE60011570T2 (de) 1999-01-07 2004-11-25 Wyeth Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
JP4001486B2 (ja) 2000-04-10 2007-10-31 ファイザー・プロダクツ・インク ベンゾアミドピペリジン含有化合物及び関連化合物
DE10043659A1 (de) 2000-09-05 2002-03-14 Merck Patent Gmbh Arylpiperazinderivate
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
EP1203584A1 (en) 2000-10-13 2002-05-08 M.D.M. S.r.l. Cholinergic precursor (in particular choline alfoscerate) associated with an acetylcholinesterase inhibitor (such as rivastigmine, donepezil)
US6469007B2 (en) 2000-11-28 2002-10-22 Wyeth Serotonergic agents
US20060287335A1 (en) 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
BR0116063A (pt) 2000-12-13 2004-08-03 Wyeth Corp Inibidores de sulfonamida heterocìclica da produção de beta amilóide e seus usos
US6780860B2 (en) 2001-04-26 2004-08-24 Wyeth Azabicyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-ht1a antagonists
US6821981B2 (en) 2001-04-26 2004-11-23 Wyeth Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]-quinoline as 5-HT1A antagonists
AR035083A1 (es) 2001-07-25 2004-04-14 Wyeth Corp Derivados azaheterociclilmetilicos de 7,8-dihidro-6h-5-oxa-1-aza-fenantreno, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de un medicamento antidepresivo e intermediarios
US20030060513A1 (en) 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
DE10217006A1 (de) 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
US6982268B2 (en) 2002-05-08 2006-01-03 Neurogen Corporation Substituted imidazolylmethyl pyridine and pyrazine derivatives GABAA receptor ligands
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
TW200401641A (en) 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
AU2003256430A1 (en) 2002-08-15 2004-03-03 Wyeth AGONISM OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION
US7153849B2 (en) 2002-09-12 2006-12-26 Wyeth Antidepressant arylpiperazine derivatives of hetrocycle-fused benzodioxans
US20040147581A1 (en) 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
WO2004045718A2 (en) 2002-11-20 2004-06-03 Cypress Bioscience, Inc. Treatment of cognitive dysfunctions'
US7227023B2 (en) 2003-04-30 2007-06-05 Wyeth Quinoline 3-amino chroman derivatives
US7276603B2 (en) 2003-05-02 2007-10-02 Wyeth Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use
US20050032873A1 (en) 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
AU2004261606A1 (en) 2003-07-31 2005-02-10 Wyeth N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-Hydroxytryptamine-6 ligands
PL1541197T3 (pl) 2003-12-02 2009-10-30 Pharmaneuroboost N V Zastosowanie pipamperonu i SNDRI, SNRI lub SSRI do leczenia zaburzeń nastroju lub zaburzeń lękowych z niepokojem
MY179926A (en) 2003-12-08 2020-11-19 Wyeth Corp Process for the preparation of tubulin inhibitors
WO2005082372A1 (en) 2004-01-29 2005-09-09 Pfizer Products Inc. COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
US7247650B2 (en) 2004-03-02 2007-07-24 Wyeth Macrolides and methods for producing same
CN1929837A (zh) 2004-03-02 2007-03-14 惠氏公司 作为神经保护剂和/或神经再生剂的非免疫抑制的亲免素配体
US20050215561A1 (en) 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
TWI391387B (zh) 2004-05-12 2013-04-01 Eisai R&D Man Co Ltd 具有哌啶環之吲哚衍生物
JP2008503460A (ja) 2004-06-16 2008-02-07 ワイス β−セクレターゼのインヒビターとしてのジフェニルイミダゾピリミジンおよびイミダゾールアミン
EP1756087B1 (en) 2004-06-16 2009-10-07 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
WO2006042249A2 (en) 2004-10-08 2006-04-20 Neuromolecular Pharmaceuticals, Inc. Methods and compositions for treating migraine pain
EP1853230A2 (en) 2005-02-15 2007-11-14 Jazz Pharmaceuticals Inc. Dosage form and method for sustained release of a substituted pyrazine compound
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
JP4796927B2 (ja) 2005-11-28 2011-10-19 株式会社豊田中央研究所 クロック信号出力回路
CN101466365A (zh) 2006-06-09 2009-06-24 惠氏公司 增强认知功能的方法
TW200808741A (en) 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200808730A (en) 2006-06-09 2008-02-16 Wyeth Corp Process for synthesizing piperazine-piperidine compounds
TW200808740A (en) 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
CL2007003409A1 (es) 2006-11-28 2008-04-11 Wyeth Corp Perla de liberacion controlada que comprende una unidad de nucleo central, una primera capa con un agente farmacologico que es un compuesto derivado de piperazina-piperidina, un acidificante, una segunda capa; procedimiento de preparacion; formulacio

Also Published As

Publication number Publication date
PE20070069A1 (es) 2007-03-15
BRPI0613491A2 (pt) 2011-01-11
NO20076344L (no) 2008-02-27
WO2006135839A3 (en) 2007-11-22
US20070027160A1 (en) 2007-02-01
IL187972A0 (en) 2008-03-20
AU2006257874A1 (en) 2006-12-21
ECSP088094A (es) 2008-02-20
JP2008543782A (ja) 2008-12-04
MX2007015678A (es) 2008-02-20
RU2007146543A (ru) 2009-07-20
WO2006135839A2 (en) 2006-12-21
EP1888559A2 (en) 2008-02-20
KR20080021134A (ko) 2008-03-06
GT200600255A (es) 2007-07-19
US7671056B2 (en) 2010-03-02
CN101243073A (zh) 2008-08-13
CR9560A (es) 2008-02-20
CA2611711A1 (en) 2006-12-21
AR055059A1 (es) 2007-08-01
ZA200710699B (en) 2009-05-27

Similar Documents

Publication Publication Date Title
NO20076344L (no) Piperazin-piperidin-antagonister og agonister av 5-HT1A-reseptoren
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
PL2049529T3 (pl) Podstawione związki diazepanowe - antagoniści receptora oreksyny
MX2009008104A (es) Hepcidina, antagonistas de hepcidina y metodos de uso.
MY146972A (en) Novel compounds as opioid receptor modulators.
GB0504828D0 (en) Therapeutic agents
WO2005103041A3 (en) Treatment of cns disorders using cns target modulators
TN2011000171A1 (en) Isonicotinamide orexin receptor antagonists
WO2007076070A3 (en) Modulators of muscarinic receptors
TW200801013A (en) Substituted benzofused derivatives and their use as vanilloid receptor ligands
MX368459B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
WO2007025069A3 (en) Diazaspirodecane orexin receptor antagonists
TW200621244A (en) Modulators of muscarinic receptors
CY1112500T1 (el) Νεες ετεροκυκλικες ενωσεις ως ανταγωνιστες μglu5
TW200720260A (en) Prokineticin 1 receptor antagonists
TW200716566A (en) Prokineticin 2 receptor antagonists
TW200724140A (en) Hydantoin compounds
WO2007030761A3 (en) Acyclic 1,4-diamines and uses thereof
MX2007006382A (es) Moduladores de receptores muscarinicos.
SI2016064T1 (sl) Postopki za pripravo spojin, ki vsebujejo pirazol
TW200736240A (en) Novel processes for the preparation of cyclopropyl-amide derivatives
WO2007115192A3 (en) P2x7 antagonists to treat affective disorders
SE0403005D0 (sv) New use
UA97251C2 (ru) Соединения как модуляторы опиоидного рецептора